Phase 2 N=10 Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
Multiple Myeloma
Primary: Number of Participants With Hematologic Response — 6 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=86 Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy
Recurrent Hypopharyngeal Squamous Cell Carcinoma · Recurrent Laryngeal Squamous Cell Carcinoma · Recurrent Laryngeal Verrucous Carcinoma
Primary: Progression-free Survival (PFS) — 105; 105 days — p=0.73
Phase 3 N=2,238 Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris
Acne Vulgaris
Primary: Percentage of Patients With a Score of 0 (None) or 1 (Minimal) on the 5-point Global Acne Assessment Score (GAAS) — 29.8; 20.9 Percentage of Patients
Phase 4 N=24 A Study of Peginterferon Alfa-2a in Participants With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program
Hepatitis B, Chronic
Primary: Number of HBeAg Positive Participants With Hepatitis B Virus-deoxy Ribonucleic Acid (HBV-DNA) Less Than (<) 100,000 Copies Per Milliliter (Copies/mL) — 7 participants
Phase 2 N=111 Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia
Leukemia
Primary: Complete Remission (CR) — 77; 32; 2 Participants
N/A N=206 HIV and Kidney Function Study
HIV Infections · AIDS
Primary: Performance of Glomerular Filtration Rate (GFR) Estimating Equations — 10.9; 5.4; 4.3; 6.4 mL/min per 1.73 m^2
N/A N=27 Clinical Performance of a Transcutaneous Bone Conduction Hearing Solution (Baha® Attract System)
Deafness · Hearing Loss · Hearing Loss, Conductive
Primary: Hearing Performance, PTA4 at 12 Weeks — -18.4 dB — p=<0.0001
N/A N=35 Effects of Pennsaid on Clinical Neuropathic Pain
Neuralgia · Postherpetic Neuralgia · Reflex Sympathetic Dystrophy
Primary: VAS After Treatment — 4.9; 5.6 Visual Analog Scale — p=.04
Phase 3 N=393 A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise
Type 2 Diabetes
Primary: Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF]) — -0.29; -1.04; -1.11 % of hemoglobin — p=<0.0001
Phase 2 N=51 Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer
Prostate Cancer
Primary: Observed Maximum Serum Leuprolide Concentration (Cmax) for Dose 1 and Dose 3 — 6.14; 9.66; 13.6; 5.36 ng/mL
Phase 2 N=35 Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis
Amyloidosis
Primary: Number of Participants With Disease Response — 20 Participants
N/A N=400 InductOs® in Real World Spine Surgery; A Retrospective, French, Multi-centric, Study
Spine Fusion
Primary: The Primary Diagnostic Indication for InductOs Use — 32.3; 4.5; 3.5; 29.8 percentage of participants
Phase 1 N=13 An Absolute Bioavailability Study in Healthy Participants Comparing Oral to Intravenous Administration of GDC-0973 (Cobimetinib)
Healthy Volunteers
Primary: Maximum Observed Plasma Concentration (Cmax) of IV and Oral GDC-0973 — 20.5; 15.2 nanograms per milliliter (ng/mL)
Phase 1 N=69 A Website to Teach Children Safety With Dogs
Child Dog Bite Prevention
Primary: Children's Behavior With Dogs on Standardized Objective Scale — 1.4; 1.6 units on a scale
Phase 1 N=18 A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
Axial Spondyloarthritis (AxSpA) · Non-radiographic Evidence-AxSpA · Ankylosing Spondylitis
Primary: The Concentration of Certolizumab Pegol (CZP) in Breast Milk on Day 0 — NA; NA µg/mL